US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Nutrien Ltd (0NHS) 銘柄情報

Nutrien Ltd (0NHS)

0.00

0.00

(0.00%)

終了 6月16日 12:30AM

Nutrien Ltd (0NHS) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

-

( - )

買値

0.00

売値

0.00

出来高

12

0.00 日の範囲 0.00

54.11 52 週間の範囲 54.11

時価総額

前日終値

0.00

始値

-

時刻

最終取引時間

11:40:00

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 1,620,988

発行済株式数

480,023,548

配当利回り

2.19

PER

13.75

1 株当たり利益 (EPS)

4.93

歳入

26.88B

純利益

2.39B

Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Retail, Potash, Nitrogen, and Phosphate. The Retail segment markets crop nutrients, crop protection products, seed, and merchandise, as well as provides agronomic application and financing services and soluti... Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Retail, Potash, Nitrogen, and Phosphate. The Retail segment markets crop nutrients, crop protection products, seed, and merchandise, as well as provides agronomic application and financing services and solutions; and produces proprietary products, including proprietary crop nutrient, crop protection, and seed products. The Potash segment includes mining and processing of potash. The Nitrogen segment owns and operates ammonia production facilities that offers ammonia, urea, ammonium nitrate (UAN), urea solutions, nitric acid, and ammonium nitrate, as well as environmentally smart nitrogen and ammonium sulfate. The Phosphate segment manufactures and sells solid and liquid phosphate fertilizers, phosphate feed, and purified phosphoric acid, which is used in feed and industrial products. The company was incorporated in 2017 and is headquartered in Saskatoon, Canada. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.nutrien.com

本社

Saskatoon, Canada

設立

2026

Nutrien Ltd is listed in the sector of the ロンドン証券取引所 with ticker 0NHS. The last closing price for Nutrien was US$0. Over the last year, Nutrien shares have traded in a share price range of US$ 54.11 to US$ 54.11.

Nutrien currently has 480,023,548 shares in issue. Nutrien has a price to earnings ratio (PE ratio) of 13.75.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	54.11	54.11	54.11	5705	54.11	DE
52	0	0	54.11	54.11	54.11	2834	54.11	DE
156	0	0	54.11	54.11	54.11	1517	54.11	DE
260	0	0	54.11	54.11	54.11	1347	54.11	DE

0NHS - Frequently Asked Questions (FAQ)

What is the current Nutrien Ltd share price?

The current share price of Nutrien Ltd is US$ 0.00

How many Nutrien Ltd shares are in issue?

Nutrien Ltd has 480,023,548 shares in issue

What is the 1 year trading range for Nutrien Ltd share price?

Nutrien Ltd has traded in the range of US$ 54.11 to US$ 54.11 during the past year

What is the PE ratio of Nutrien Ltd?

The price to earnings ratio of Nutrien Ltd is 13.75

What is the cash to sales ratio of Nutrien Ltd?

The cash to sales ratio of Nutrien Ltd is 1.21

What is the registered address of Nutrien Ltd?

The registered address for Nutrien Ltd is 211 19th Street East, Saskatoon, Saskatchewan, S7K 5R6

What is the Nutrien Ltd website address?

The website address for Nutrien Ltd is www.nutrien.com

US Market News

US Market News 13分前

Unilever Scales Digital Twins Across Global Manufacturing Network with AccentureJune 16, 2026 2:59 AM
Business WireUnilever (LON: ULVR) is partnering with Accenture (NYSE: ACN) to scale the use of AI-enabled digital twins across its global manufacturing network

CelestialSage6

CelestialSage6 15分前

You can't refute it. Yes, I understand your level well.

biotechinvestor1

biotechinvestor1 21分前

Total nonsense! I have no interest in educating you.

Nemesis18

Nemesis18 22分前

She'll probably move to somewhere without any extradition treaty once the plug is finally pulled on this 'cancer vaccine' scam.?

price_and_volume

price_and_volume 25分前

Gonna have to bump the A/S then...
He said recently that they are looking at another acquisition...and he will dilute with shares to get it. Agreed - I posted the same, "where's the finance coming from for acquisitions?"...

Supposed 400MM shares going to $GTVH (believe it when

StockItOut

StockItOut 25分前

WKSP Weekly chart: https://schrts.co/IIIuZpgy

CelestialSage6

CelestialSage6 26分前

I understand that Halozyme has not signed any exclusive agreements regarding treatments or indications related to Dupixent, so why is Sanofi collaborating with Alteogen?

Also, Halozyme's mdase patent is being invalidated due to Merck. Alteogen's technology is more advanced than Halozy

Wolf-man jack

Wolf-man jack 28分前

WQLF SAYS: Have Mercy WQLF ahoooooo

Q: Why hasn't CV SCIENCES been accepted in the CMS Medicare Pilot Program?

Ai Generated:

C V Sciences has not been "accepted" into the CMS Medicare Pilot Program because the pilot is a provider-led incentive, not a

price_and_volume

price_and_volume 29分前

What reasonable expectation is there of PPS responding?
whether management can successfully execute on the vision they have laid out. Nobody cares about "the company" or "the management" or "their vision" or your two-bit-MBA-tutorials-in-a-post.

Enough of all that garbage.

mrwrn2010

mrwrn2010 32分前

Disagree. The outcome of OxyContin litigation was unknown 9 months to a year ago. You can guess at a variety of outcomes, sure, but it’s not certain. Same thing with human trials - we don’t have positive trial results for anything in the pipeline until we have them. What passes in vitro may not pass

PEACHMAN

PEACHMAN 34分前

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177680761

IFUS STRONG

price_and_volume

price_and_volume 35分前

I get that, but that's not what I asked.

I'm not bullying you or accusing you of pumping.

You repeatedly point out what you consider to be nefarious shenanigans, so I asked: PPS hasn't effectively changed in THREE YEARS , other than a few short days 1 year ago this wee

Homework.Investwell

Homework.Investwell 41分前

2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800

Suite 800 is empty....🤔

Linda lives in Missouri now but headquarters could be moved anywhere...or will they need it?

I think we're going to find out by the end of the sum

Mdk1

Why this paper is highly interesting for Lightwave Logic (GROK)
This is a top-scored paper that strongly validates Lightwave Logic’s Perkinamine™ chromophore series 3 as a leading electro-optic material for next-generation datacenter optics.

Key Reasons Why It Matters:

janice shell

janice shell 51分前

Now that's a real head-scratcher! But shorts have to be smart, so I'd say torso and head.

gitreal

gitreal 53分前

Anyone with half a Brian can see this company is being crazy shorted!

Which half? Torso and head?

HyGro

NWBO could file an FDA application anytime but they haven't and have shown no intent to do so. Instead they are just burning more shareholder cash and if approved, will lose money on every dose because NICE will hammer the reimbursement down below Advent's costs. NWBO will lose money and collaps

US Market News

US Market News 58分前

TotalEnergies SE: Disclosure of Transactions in Own SharesJune 16, 2026 2:00 AM
Business Wire Regulatory News In accordance with the authorizations given by the shareholders’ general meeting on May 29, 2026, to trade on its shares and pursuant to applicable law on share

HyGro

Sorry, not enough. NWBO won't make any profit selling in the UK. NICE hates personalized oncology treatments and won't pay enough for NWBO to make a profit.
That's what counts. And NWBO will go under or just become Advent Contract Manufacturer. They have no cash or credit to fund any sub

biotechinvestor1

biotechinvestor1 1時間前

Don’t start spazzing again, Alteogen circus clown. The Sanofi news is old.
Once Merck settles/licenses from Halozyme, Sanofi and all others will follow.
Your Alteogen stole IP from Halozyme and will pay a price for it. You can count on it.
The companies who have signed with Alte

Steady_T

Steady_T 1時間前

Your theory will be put to the test after UK approval. I give it 6 months as a guess.

HyGro

HyGro 1時間前

What's true is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How many years are you going to wait to find out???

HyGro

HyGro 1時間前

What's True is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How long are you going to wait to find out???

Mdk1

Mdk1 1時間前

Google Scholar alert - new article: "A Comparison of Plasmonic Modulator Structures in the O- and C-Band for the 400G/Lane IM/DD Era"
>>> " In ALL cases, the same electro-optic organic material, Lightwave Logic’s PerkinamineTM
chromophore series 3, was used " !
https://ieeexplor

CelestialSage6

CelestialSage6 1時間前

Stop talking nonsense. Sanofi is conducting clinical trials using Alteogen's technology; what are your thoughts on this? Did you sense a crisis for Halozyme?

POET Technologies

Tactical Alpha Portfolio...

Granite Falls Energy (EM)

PÃO DE AÇUCAR ON

S21870 Eqty Lkd Nts 21/1...

Industria De Diseno Textil

Lindt and Sprungli (PK)

Garden City (PK)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。